Rapact 10mg tablet | Everolimus | Apple pharmaceuticals

Description

Rapact 10mg consist of an active ingredient known as Everolimus which is intruded with the growth of cancer cell and process is slowed down. Rapact 10mg tablets is not a curable medication, which helps to slow their spreading into the body.

Indication

Primarily Rapact 10mg tablets indicated for the treatment
* kidney carcinoma
* Breast carcinoma
* Brain carcinoma
Everolimus is also indicated in various advanced stage cancer in stomach, intestines or pancreas.

Mechanism Of Action

Everolimus is an inhibitor of mTOR, joins at high compatibility to FK506 binding protein 12, via producing drug complex that inhibits the production of mTOR.
This inhibition reduces the activity of effectors downstream, which may lead to stoppage of cell progression from G1 into S phase, finally causes cell growth arrest and apoptosis

Dosage

Rapact 10mg tablets should be given with or without food.

Dosage regimen of Rapact 10mg:

In breast cancer, renal cell cancer, pancreatic cancer, Neuroendocrine cancer:
The prescribed dosage is 10mg should be taken as a single dose.

In Brain or intracranial cancer:

The prescribed dosage of Rapact as a single dose. is 4.5mg/m2 given orally

In pediatric:

The pediatric dosage of Rapact as a single dose in the brain or intracranial tumor is 4.5mg/m2 should be given orally.

Drug Interaction

Rapact 10mg interaction with strong inhibitor of CYP3A4, or P-g p, cause reducing the efflux of Everolimus and high plasma concentration of Everolimus.
Interaction of Rapact 10mg with strong CYP3A4 inducers will be increasing the disclosure of Everolimus.
Combination of Rapact 10mg with cyclosporine will be increasing the AUC level of Everolimus frequently.

Contraindication

If patients are contraindicated to the components present in the Rapact 10mg tablets. Some anaphylactic reaction occurs.

Pregnancy

Pregnancy category of Everolimus C
In patients, Rapact 10mg is used only after knowing the benefits to the mother exceed the risk to the fetus.

Lactation

Breastfeeding should not be suggested

Storage

Rapact 10mg tablet store at 25°C.
Store the medicine away from moisture, heat, and light

Missed Dose

In the case of the missed dose, patients must consult with the medical practitioner and follow the instructions given by them.
Thereby missed dose should be avoided and follow the regular dosing schedule.

FOR MORE INFORMATION:

EMAIL:

applepharmaceutical@gmail.com

PHONE:

91- 9987711567

VISIT US:

anti-cancer-drugs.com/rapact-10mg.php

Rapact 5mg tablet - Everolimus | Apple Pharmaceuticals

Description

Rapact 5mg consist of an active ingredient known as Everolimus which is intruded with the growth of cancer cell and the process is slowed down. Rapact 5mg tablets is not a curable medication, which helps to slow their spreading into the body.

Indication

Primarily Rapact 5mg tablets indicated for the treatment
* kidney carcinoma
* Breast carcinoma
* Brain carcinoma
Everolimus is also indicated in various advanced stage cancer in stomach, intestines or pancreas.

Mechanism Of Action

Everolimus is an inhibitor of mTOR, joins at high compatibility to FK506 binding protein 12, via producing drug complex that inhibits the productive of mTOR.
This inhibition reduces the activity of effectors downstream, which may lead to stoppage of cell progression from G1 into S phase, finally causes cell growth arrest and apoptosis

Dosage

Rapact 5mg tablets should be given with or without food.

Dosage regimen of Rapact 5mg:

In breast cancer, renal cell cancer, pancreatic cancer, Neuro endocrine cancer:
The prescribed dosage is 10mg should be taken as a single dose.

In Brain or intracranial cancer:

The prescribed dosage of Rapact as a single dose. is 4.5mg/m2 given orally

In pediatric:

The pediatric dosage of Rapact as a single dose in brain or intracranial tumor is 4.5mg/m2 should be given orally.

Drug Interaction

Rapact 5mg interaction with strong inhibitor of CYP3A4, or P-g p, cause reducing the efflux of Everolimus and high plasma concentration of Everolimus.
Interaction of Rapact 5mg with strong CYP3A4 inducers will increase the disclosure of Everolimus.
Combination of Rapact 5mg with cyclosporine will be increasing the AUC level of Everolimus frequently.

Contraindication

If patients are contraindicated to the components present in the Rapact 5mg tablets. Some anaphylactic reaction occurs.

Pregnancy

Pregnancy category of Everolimus C
In patients, Rapact 5mg is used only after knowing the benefits to the mother exceed the risk to the fetus.

Lactation

Breast feeding should not be suggested

Storage

Rapact 5mg tablet store at 25°C.
Store the medicine away from moisture, heat, and light

Missed Dose

In the case of the missed dose, patients must consult with a medical practitioner and follow the instructions given by them.
Thereby missed dose should be avoided and follow the regular dosing schedule.

FOR MORE INFORMATION:

EMAIL:

applepharmaceutical@gmail.com

PHONE:

91- 9987711567

VISIT US:

anti-cancer-drugs.com/rapact-5mg.php

Everotas 5mg tablet - Everolimus | Apple Pharmaceuticals

Description

Everotas 5mg consists of an active ingredient known as Everolimus which is intruded with the growth of cancer cell and the process is slowed down.
Everotas 5mg tablets is not a curable medication, which helps to slow their spreading into the body.

Indication

 Primarily Everotas 5mg tablets indicated for the treatment
* kidney carcinoma
* Breast carcinoma
* Brain carcinoma
Everolimus is also indicated in various advanced stage cancer in stomach, intestines or pancreas.

Mechanism

Everolimus is an inhibitor of mTOR, joins at high compatibility to FK506 binding protein 12, via producing drug complex that inhibits the production of mTOR. This inhibition reduces the activity of effectors downstream, which may lead to stoppage of cell progression from G1 into S phase, finally causes cell growth arrest and apoptosis

Dosage and administration

Everotas 5mg tablets should be given with or without food.
Dosage regimen of Everotas 5mg:
In breast cancer, renal cell cancer, pancreatic cancer, Neuroendocrine cancer:
The prescribed dosage is 10mg should be taken as a single dose.
In Brain or intracranial cancer:
The prescribed dosage of Everotas as a single dose. is 4.5mg/m2 given orally
In pediatric:
The pediatric dosage of Everotas as a single dose in the brain or intracranial tumor is 4.5mg/m2 should be given orally.

Side Effects

Hypersensitivity reactions, Lymphomas & other malignancy, Serious infections, Kidney graft thrombosis, Hepatic artery thrombosis, Nephrotoxicity, Hyperlipemia, Angioedema, Interstitial lung disease, Thrombocytopenia, Male infertility, Proteinuria, New commencement of diabetes.

Drug interaction

Everotas 5mg interaction with strong inhibitor of CYP3A4, or P-g p, cause reducing the efflux of Everolimus and high plasma concentration of Everolimus.
Interaction of Everotas 5mg with strong CYP3A4 inducers will be increasing the disclosure of Everolimus.
Combination of Everotas 5mg with cyclosporine will increase the AUC level of Everolimus frequently.
Combination ketoconazole with Everotas 5mg tablet or other CYP3A4 inhibitors will be increasing the plasma concentration and AUC of Everolimus.

Pregnancy and lactation

Pregnancy category of Everolimus C
In patients, Everotas 5mg is used only after knowing the benefits to the mother exceed the risk to the fetus.
Breastfeeding should not be suggested

Storage

Everotas 5mg tablet store at 25°C.
Store the medicine away from moisture, heat, and light

Missed Dose

In the case of the missed dose, patients must consult with the medical practitioner and follow the instructions given by them. Thereby missed dose should be avoided and follow the regular dosing schedule.

FOR MORE INFORMATION:

EMAIL:

applepharmaceutical@gmail.com

PHONE:

91- 9987711567

VISIT US:

anti-cancer-drugs.com/everotas-5mg.php

Everotas 10mg tablet - Everolimus | Apple Pharmaceuticals

Description

Everotas 10mg consist of an active ingredient known as Everolimus which is intruded with the growth of cancer cell and the process is slowed down.
Everotas 10mg tablets is not a curable medication, which helps to slow their spreading into the body.

Indication

 Primarily Everotas 10mg tablets indicated for the treatment
* kidney carcinoma
* Breast carcinoma
* Brain carcinoma
Everolimus is also indicated in various advanced stage cancer in stomach, intestines or pancreas.

Mechanism

Everolimus is an inhibitor of mTOR, joins at high compatibility to FK506 binding protein 12, via producing drug complex that inhibits the production of mTOR. This inhibition reduces the activity of effectors downstream, which may lead to stoppage of cell progression from G1 into S phase, finally causes cell growth arrest and apoptosis

Dosage and administration

Everotas 10mg tablets should be given with or without food.
Dosage regimen of Everotas 10mg:
In breast cancer, renal cell cancer, pancreatic cancer, Neuroendocrine cancer:
The prescribed dosage is 10mg should be taken as a single dose.
In Brain or intracranial cancer:
The prescribed dosage of Everotas as a single dose. is 4.5mg/m2 given orally
In pediatric:
The pediatric dosage of Everotas as a single dose in the brain or intracranial tumor is 4.5mg/m2 should be given orally.

Side Effects

Hypersensitivity reactions, Lymphomas & other malignancy, Serious infections, Kidney graft thrombosis, Hepatic artery thrombosis, Nephrotoxicity, Hyperlipemia, Angioedema, Interstitial lung disease, Thrombocytopenia, Male infertility, Proteinuria, New commencement of diabetes.

Drug interaction

Everotas 10mg interaction with strong inhibitor of CYP3A4, or P-g p, cause reducing the efflux of Everolimus and high plasma concentration of Everolimus.
Interaction of Everotas 10mg with strong CYP3A4 inducers will increase the disclosure of Everolimus.
Combination of Everotas 10mg with cyclosporine will be increasing the AUC level of Everolimus frequently.
Combination ketoconazole with Everotas 10mg tablet or other CYP3A4 inhibitors will increase the plasma concentration and AUC of Everolimus.

Pregnancy and lactation

Pregnancy category of Everolimus C
In patients, Everotas 10mg is used only after knowing the benefits to the mother exceed the risk to the fetus.
Breastfeeding should not be suggested

Storage

Everotas 10mg tablet store at 25°C.
Store the medicine away from moisture, heat, and light

Missed Dose

In the case of the missed dose, patients must consult with the medical practitioner and follow the instructions given by them. Thereby missed dose should be avoided and follow the regular dosing schedule.

FOR MORE INFORMATION:

EMAIL:

applepharmaceutical@gmail.com

PHONE:

91- 9987711567

VISIT US:

anti-cancer-drugs.com/everotas-10mg.php

Evergraf 0.5mg tablet - Everolimus | Apple Pharmaceuticals

Description

Evergraf 0.5mg consist of an active ingredient known as Everolimus which is intruded with the growth of cancer cell and the process is slowed down.
Evergraf 0.5mg tablets is not a curable medication, which helps to slow their spreading into the body.

Indication

Primarily Evergraf 0.5mg tablets indicated for the treatment
* kidney carcinoma
* Breast carcinoma
* Brain carcinoma
Everolimus is also indicated in various advanced stage cancer in stomach, intestines or pancreas.

Mechanism Of Action

Everolimus is an inhibitor of mTOR, joins at high compatibility to FK506 binding protein 12, via producing drug complex that inhibits the production of mTOR.
This inhibition reduces the activity of effectors downstream, which may lead to stoppage of cell progression from G1 into S phase, finally causes cell growth arrest and apoptosis

Dosage

Evergraf 0.5mg tablets should be given with or without food.
The dosage regimen of Evergraf 0.5mg;
In breast cancer, renal cell cancer, pancreatic cancer, Neuroendocrine cancer:
The prescribed dosage is 10mg should be taken as a single dose.
In Brain or intracranial cancer:
The prescribed dosage of Evergraf as a single dose. is 4.5mg/m2 given orally
In pediatric:
The pediatric dosage of Evergraf as a single dose in the brain or intracranial tumor is 4.5mg/m2 should be given orally.

Precautions

Lymphomas:
The developed hazard of skin cancers, the patient may protect from UV light

Serious infections :
Patients getting Evergraf 0.5mg have a severe risk of achieving various infections related to bacteria, virus, and fungi.

Hepatic artery thrombosis :
Evergraf 0.5mg therapy should not be recommended in liver transplant patients,

Nephrotoxicity :
While using Evergraf 0.5mg in renal impaired patients Renal function should be monitored frequently; drug use with caution.

Drug Interaction

Evergraf 0.5mg interaction with strong inhibitor of CYP3A4, or P-g p, cause reducing the efflux of Everolimus and high plasma concentration of Everolimus.
Interaction of Evergraf 0.5mg with strong CYP3A4 inducers will be increasing the disclosure of Everolimus.
Combination of Evergraf 0.5mg with cyclosporine will increase the AUC level of Everolimus frequently.
Combination ketoconazole with Evergraf 0.5mg tablet or other CYP3A4 inhibitors will increase the plasma concentration and AUC of Everolimus.

Pregnancy

Pregnancy category of Everolimus C
In patients, Evergraf 0.5mg is used only after knowing the benefits to the mother exceed the risk to the fetus.

Lactation

Breastfeeding should not be suggested

Storage

Evergraf 0.5mg tablet store at 25°C.
Store the medicine away from moisture, heat, and light

Missed Dose

In the case of the missed dose, patients must consult with a medical practitioner and follow the instructions given by them.
Thereby missed dose should be avoided and follow the regular dosing schedule.

FOR MORE INFORMATION:

EMAIL:

applepharmaceutical@gmail.com

PHONE:

91- 9987711567

VISIT US:

anti-cancer-drugs.com/evergraf-0.5mg.php

Evergraf 0.25mg tablet:Everolimus Price | Apple pharmaceuticals

Description

Evergraf 0.25mg consists of an active ingredient known as Everolimus which is intruded with the growth of cancer cell and the process is slowed down.
Evergraf 0.25mg tablets is not a curable medication, which helps to slow their spreading into the body.

Indication

Primarily Evergraf 0.25mg tablets indicated for the treatment
* kidney carcinoma
* Breast carcinoma
* Brain carcinoma
Everolimus is also indicated in various advanced stage cancer in stomach, intestines or pancreas.

Mechanism Of Action

Everolimus is an inhibitor of mTOR, joins at high compatibility to FK506 binding protein 12, via producing drug complex that inhibits the production of mTOR.
This inhibition reduces the activity of effectors downstream, which may lead to stoppage of cell progression from G1 into S phase, finally causes cell growth arrest and apoptosis

Dosage

Evergraf 0.25mg tablets should be given with or without food.
The dosage regimen of Evergraf 0.25mg;
In breast cancer, renal cell cancer, pancreatic cancer, Neuroendocrine cancer:
The prescribed dosage is 10mg should be taken as a single dose.
In Brain or intracranial cancer:
The prescribed dosage of Evergraf as a single dose. is 4.5mg/m2 given orally
In pediatric:
The pediatric dosage of Evergraf as a single dose in the brain or intracranial tumor is 4.5mg/m2 should be given orally.

Precautions

Lymphomas:
The developed hazard of skin cancers, the patient may protect from UV light

Serious infections:
Patients getting Evergraf 0.25mg have a severe risk of achieving various infections related to bacteria, virus, and fungi.

Hepatic artery thrombosis:
Evergraf 0.25mg therapy should not be recommended in liver transplant patients,

Nephrotoxicity:
While using Evergraf 0.25mg in renal impaired patients Renal function should be monitored frequently; drug use with caution.

Drug Interaction

Evergraf 0.25mg interaction with strong inhibitor of CYP3A4, or P-g p, cause reducing the efflux of Everolimus and high plasma concentration of Everolimus.
Interaction of Evergraf 0.25mg with strong CYP3A4 inducers will be increasing the disclosure of Everolimus.
Combination of Evergraf 0.25mg with cyclosporine will be increasing the AUC level of Everolimus frequently.
Combination ketoconazole with Evergraf 0.25mg tablet or other CYP3A4 inhibitors will increase the plasma concentration and AUC of Everolimus.

Pregnancy

Pregnancy category of Everolimus C
In patients, Evergraf 0.25mg is used only after knowing the benefits to the mother exceed the risk to the fetus.

Lactation

Breastfeeding should not be suggested

Storage

Evergraf 0.25mg tablet store at 25°C.
Store the medicine away from moisture, heat, and light

Missed Dose

In the case of the missed dose, patients must consult with the medical practitioner and follow the instructions given by them.
Thereby missed dose should be avoided and follow the regular dosing schedule.

FOR MORE INFORMATION:

EMAIL:

applepharmaceutical@gmail.com

PHONE:

91- 9987711567

VISIT US:

anti-cancer-drugs.com/evergraf-0.25mg.php

Evertor 10mg Tablet | Apple Pharmaceuticals

Description

Evertor consist of an active ingredient known as Everolimus which is intruded with the growth of cancer cell and the process is slowed down. Evertor tablets is not a curable medication, which helps to slow their spreading into the body.

Indication of Evertor

Primarily Evertor tablets indicated for the treatment :
kidney carcinoma
Breast carcinoma
Brain carcinoma
Everolimus is also indicated in various advanced stage cancer in stomach, intestines or pancreas.

Mechanism

Everolimus is an inhibitor of mTOR, joins at high compatibility to FK506 binding protein 12, via producing drug complex that inhibits the production of mTOR. This inhibition reduces the activity of effectors downstream, which may lead to stoppage of cell progression from G1 into S phase, Finally causes cell growth arrest and apoptosis

Dosage regimen of Evertor

In breast cancer, renal cell cancer, pancreatic cancer, Neuroendocrine cancer:
 The prescribed dosage is 10mg should be taken as a single dose.
 In Brain or intracranial cancer:
 The prescribed dosage of Evertor as a single dose. is 4.5mg/m2 given orally
 In pediatric:
 The pediatric dosage of Evertor as a single dose in the brain or intracranial tumor is 4.5mg/m2 should be given orally.

Side Effects

Hypersensitivity reactions, Lymphomas & other malignancy, Serious infections, Kidney graft thrombosis, Hepatic artery thrombosis, Nephrotoxicity, Hyperlipemia, Angioedema, Interstitial lung disease, Thrombocytopenia, Male infertility, Proteinuria, New commencement of diabetes.

Drug-Drug interaction

Evertor interaction with strong inhibitor of CYP3A4, or P-gp, cause reducing the efflux of Everolimus and high plasma concentration of Everolimus. Interaction of Evertor with strong CYP3A4 inducers will increase the disclosure of Everolimus. Combination of Evertor with cyclosporine will increase the AUC level of Everolimus frequently. Combination ketoconazole with Evertor tablet or other CYP3A4 inhibitors will increase the plasma concentration and AUC of Everolimus.

Pregnancy and lactation

Pregnancy category of Everolimus In patients Evertor is used only after knowing the benefits to the mother exceed the risk to the fetus. Breastfeeding should not be suggested

Storage and handling

Evertor tablet store at 25°C Store the medicine away from moisture, heat, and light

Missed Dose

In the case of the missed dose, patients must consult with the medical practitioner and follow the instructions given by them. thereby missed dose should be avoided and follow the regular dosing schedule.

FOR MORE INFORMATION:

EMAIL:

applepharmaceutical@gmail.com

PHONE:

91- 9987711567

VISIT US:

anti-cancer-drugs.com/evertor-10mg.php